As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
22 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:
22 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -253 -253 |
3%
3%
|
|
| EBIT (Operating Income) EBIT | -264 -264 |
2%
2%
|
|
| Net Profit | -258 -258 |
2%
2%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Gaurav Shah |
| Employees | 299 |
| Founded | 1999 |
| Website | www.rocketpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


